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In thispaper, we examinetheroleofcirculating tumorcells (CTCs)in breastcancer.CTCs are tumorcells present intheperipheral
blood.Theyarefoundinmanydiﬀerentcarcinomasbutarenotpresentinpatientswithbenigndisease.Recent advancesintheories
regarding metastasis support the role of early release of tumor cells in the neoplastic process. Furthermore, it has been found that
phenotypic variation exists between the primary tumor and CTCs. Of particular interest is the incongruency found between
primary tumor and CTC HER2 status in both metastatic and early breast cancer. Overall, CTCs have been shown to be a poor
prognostic marker in metastatic breast cancer. CTCs in early breast cancer are not as well studied, however, several studies suggest
that the presence of CTCs in early breast cancer may also suggest a poorer prognosis. Studies are currently underway looking at
the use of CTC level monitoring in order to guide changes in therapy.
1.Introduction
Breast cancer is one of the most common cancers aﬀecting
women. It is estimated that one in eight women will
develop an invasive breast cancer at some point during her
lifetime. In 2010, according to the American Cancer Society,
approximately 207, 090 new cases of invasive breast cancer
willbediagnosedand39,840womenwilldiefrommetastatic
disease. In this era of molecular medicine, novel approaches
are needed in the management of breast cancer. In the last
severaldecades,circulatingtumorcells(CTCs)haveemerged
as a unique target for understanding disease progression,
prognosis, and treatment in breast cancer pathogenesis.
CTCs are tumor cells present in the peripheral blood.
They are found in many diﬀerent carcinomas but are
not present in patients with benign disease [1]. Much of
the research involving CTCs stems from studies involving
disseminated tumor cells (DTCs). DTCs are tumor cells
present in the bone marrow. Brieﬂy, several studies have
shown that patients with DTCs at the time of diagnosis
have larger tumors, higher histologic grade, and a higher
incidence of lymph-node metastasis, distance metastasis,
and cancer-related death versus those patients without
DTCs [2, 3]. Furthermore, detection of DTCs after systemic
treatment is associated with increased risk of recurrence and
decreased disease-free survival as well as decreased breast
cancer-speciﬁc survival [4, 5]. Though DTCs have been
more thoroughly studied, there are several studies that have
documented a correlation between the occurrence of DTCs
and CTCs in both primary and metastatic breast cancer [6–
10]. Since bone marrow sampling is cumbersome, diﬃcult
to reproduce, and morbid for patients, emphasis has been2 Pathology Research International
placed on advancing CTC research. This paper will address
the current methodologies of CTC detection, the prognostic
role of CTCs in both early and advanced breast cancer, and
the implication of CTCs in disease progression, treatment,
tumor biology, and further research.
2.EvidenceforCTCin EarlyMetastasis
It was previously thought that metastasis occurred late in
disease progression; however, evidence from CTCs/DTCs
has shown that metastasis may be an early event. This is
supported by the fact that CTCs/DTCs are found in patients
with early breast cancer. A recent study by Husemann et
al. with transgenic (HER2/PyMT) mice showed that dis-
semination of tumor cells can occur at a preinvasive stage
of the primary tumor. They also found both in mice and
early human breast cancer that the presence of CTCs/DTCs
was independent of tumor size [11]. However, even though
occult tumor dissemination may occur early, not all patients
with detectable CTCs/DTCs will develop overt metastases.
Meng et al. looked at 36 breast cancer patients 7 to 22
years after mastectomy and found that 36% had evidence
of CTCs with no evidence of clinical disease [12]. Similarly,
in a large pooled analysis by Braun et al., only half of DTC-
positivebreastcancerpatientsrelapsedoveraten-yearperiod
[3]. These CTCs/DTCs may be in a state of dormancy and
the exact mechanism of transition to overt metastases is
unclear. Likely factors involved in this transition include
host microenvironment, host immune response, and genetic
changes in the tumor cell.
3.PhenotypicVariabilitybetweenCTCand
PrimaryTumor
Several studies have found genotypic variation between
primary tumor and CTCs/DTCs of particular interest is the
incongruent HER2 status between primary tumor and
CTCs/DTCs. A recent study utilizing the CellSearch System
inmetastaticbreastcancerfoundthat29%ofHER2-negative
primary tumors had HER2-positive CTCs and 42% of
HER2-positive primary tumors had HER2-negative CTCs
[13]. Another study by Fehm et al. looked at serum HER2
and CTCs in initially HER2-negative or HER2-unknown
metastatic breast cancer patients. Of the 77 patients, 23/77
patients were HER2 positive based on either CTC detection
or peripheral blood ELISA. HER2 concordance between
CTCs and serum HER2 was 71%. HER2 status of the
metastatic tissue was assessed in ten of these patients in
which 2/10 had discordance between primary tumor and
metastatic site [14].Similardiscrepancieshavebeenreported
in other studies, mostly ranging from 7 to 40%, as well as
intermetastatic site variability [14–19]. Discordant HER2
statusbetweenprimary tumorandCTCs/DTCshasalsobeen
reported in early breast cancer [20–23].
There has been conﬂicting evidence for treatment based
upon CTC/DTC HER2 status. In another study by Meng
et al., 9/24 patients initially HER2 negative acquired HER2
gene ampliﬁcation throughout their disease process. These
patients were either far advanced or had undergone previous
chemotherapy or radiation. Four of the patients were treated
with trastuzumab leading to one complete response and two
partial responses [24]. Another study looked at trastuzumab
response in 30 breast cancer patients stages 1–4 who had
already completed standard therapy. All 30 of these patients
had CK-19 mRNA-positive circulating and/or disseminated
tumors cells present. Though only 33% of the primary
tumors were HER2 positive, 83% of the CTCs and/or DTCs
were HER2positive.After trastuzumab therapy, 28/30(93%)
patients showed no CK-19 mRNA signal [25]. Similar
results were reported from the National Surgical Adjuvant
Breast and Bowel Project (NSABP) protocol B-31 suggesting
a potential beneﬁt from trastuzumab to HER2-negative
patients [26, 27]. However, a large randomized phase 3
trial looked at randomization of trastuzumab with paclitaxel
to metastatic breast cancer patients with HER2-negative
primary tumors. Trastuzumab did not aﬀect overall sur-
vival, response rate, or time to progression in non-HER2-
overexpressing tumors [27]. A large European multicenter
study (www.detect-study.de) is currently underway looking
at CTC HER2 expression in metastatic breast cancer patients
with HER2-negative primary tumors. This trial will look at
several diﬀerent techniques for determining HER2 status.
It will also look at HER2-positive CTC response to HER2-
targeted therapy [28].
4.CTCDetectionMethods
If CTCs are to be used as surrogates for DTCs, then accurate
and reproducible techniques are needed for CTC quan-
tiﬁcation. This is especially important when considering
that CTC concentration in peripheral blood can be as low
as one per 105–107 cells [29]. CTC detection occurs in
a two-step process, enrichment, and identiﬁcation. Several
techniques are available for CTC enrichment. The Ficoll and
OncoQuick systems utilize a density gradient centrifugation.
These systems lack speciﬁcity as they separate CTCs and
mononuclear cells from red blood cells and granulocytes
[29]. Furthermore, CTCs can migrate between layers and
the layers themselves can lose their integrity. Between the
two systems, Gertler et al. found the OncoQuick system
to be superior due its ability to select out mononuclear
cells [30]. The ISET (Isolation by Size of Epithelial Tumor
Cells) technique implores a ﬁlter consisting of 8µmp o r e st o
separate CTCs from leukocytes [31]. However, small CTCs
can be lost, and large leukocytes can be retained by the
ﬁlters leading to poor sensitivity and speciﬁcity [29]. In
general, these techniques have fallen out of favor, and most
researchers use immunological techniques for enrichment.
Immunomagnetic systems target an antigen with an
antibody that is coupled to a magnetic bead. They then
isolate the antigen-antibody complex via exposure to a
magneticﬁeld.Enrichment canoccurthrougheitherpositive
selection where the antibody is targeted against a CTC
antigen (CKs, EpCAM, HER2) or negative selection where
the antibody is targeted against a leukocyte antigen (CD 45
or 61). To date, the only FDA-approved system is CellSearch,Pathology Research International 3
animmunomagnetic system thatuses anti-EpCAMand anti-
CD45 antibodies. The main limitation is heterogeneity of
CTCsto express EpCAM.Furthermore, EpCAM is downreg-
ulatedinmalignantcellsthoughaprocesscalledepithelialto-
mesenchymal transition. Despite this, the CellSearch System
has a high reproducibility rate [1, 32].
Once enrichment is completed, characterization of CTCs
isachievedthrough molecularorimmunologicaltechniques.
RT-PCR methodologies target tumor-speciﬁc antigens. This
technique was initially considered to be sensitive; how-
ever, other authors have found several limitations to this
technique [33, 34]. These limitations included false posi-
tives due to illegitimate gene transcription, contamination
by pseudogenes, and transcription of markers present on
nonmalignant cells [35, 36]. Furthermore, false negatives
may arise if CTCs do not express the gene of interest [29].
Lastly,RT-PCRreliesoncellularlysiswhichprecludesfurther
CTC analysis and assessment of CTC quantity. However,
more recent developments in techniques allow for increased
sensitivity and speciﬁcity by overcoming these pitfalls.
Multimarker RT-PCR and novel primer designs avoid false
positives [37]. In addition, advances in PCR technology with
quantitative real-time RT-PCR (RT-qPCR) allows for cutoﬀ
values of transcripts between cancerous and noncancerous
cells, thereby designating what values are tumor-cell derived
[38, 39].
There are several immunological techniques used for the
identiﬁcation process. As described earlier, the CellSearch
Systemusesimmunomagnetictechnologyforenrichment.In
the identiﬁcation stage, these cells are ﬂuorescently stained
for cytokeratins (CK8, 18, 19), common leukocyte antigen
(CD 45), and a nuclear dye (4,6-diamino-2-phenylindole
(DAPI)). A ﬂuorescent microscope then detects and iden-
t i ﬁ e sC T C sa st h o s ec e l l st h a ta r eC K + / C D 4 5 −/DAPI+.
Fiber-optic array scanning technology (FAST) also utilizes
ﬂuorescent anticytokeratin antibodies as well as DAPI coun-
terstain. Stained cells are then exposed to laser-printing
optics that excite 300,000 cells/second. This aﬀords similar
sensitivity and speciﬁcity to conventional automated digital
microscopy with a 500-fold increase in speed [40]. Laser
Scanning Cytometry (LSC) rapidly scans and relocates
multimarker immune-labeled cells for visual examination to
separate viable from nonviable cells [41].
Multiparameter ﬂow cytometry has been utilized by
several authors for the detection of CTCs since multiple
surfaces markers and DNA ploidy can be evaluated [42–44].
As such, ﬂow cytometry aﬀords a high speciﬁcity and in one
study demonstrated a higher speciﬁcity than RT-PCR [45].
More recently, microchip technology has been described
for detection of CTCs. The “CTC-chip” uses a microﬂuid
platform by which CTCs in whole blood samples that inter-
act with microposts coated in anti-EpCAM antibody [46].
The authors demonstrated a sensitivity of 99% in a cohort
of patients with metastatic cancers. Epithelial immunospot
(EPISPOT) is a technique based on the enzyme-linked im-
munospot assay. EPISPOT detects only viable tumor cells as
evidence by their ability to secrete proteins (CK-19, MUC-1)
in short-term cell cultures [47].
5.MetastaticBreast Cancer
M o s to ft h el i t e r a t u r et h u sf a rh a se x a m i n e dC T C si n
metastatic breast cancer. Cristofanilli et al. looked at 177
metastatic breast cancerpatientsinamulticenterprospective
trial using theCellSearch Systemand foundthat thepresence
of CTCs before initiation of therapy was a predictor of
both decreased progression-free survival as well as overall
survival. Through stratiﬁcation according to progression-
free survival, a cutoﬀ value of 5 CTCs per 7.5ml of blood
was used to distinguish patientswitha favorableversusunfa-
vorable prognosis [48]. Several subsequent studies found
similar conclusions [49, 50], and further followup data
revealed elevated CTC counts at any point during therapy
was associated with decreased progression-free and overall
survival [15, 51, 52]. The prognostic value of CTCs has been
shown to be superior to tumor burden, disease phenotype,
and current imaging methodologies [53, 54]. CTCs also
allow for molecular proﬁling. Gradilone et al. looked at
CTC chemoresistance proﬁles in metastatic breast cancer
patientsusing RT-PCRtoquantifythenumberofmultidrug-
resistance-related proteins (MRPs) expressed. Those patients
with greater than two MRPs expressed per CTC had a
shorter progression-free survival then those with more drug-
sensitive CTC proﬁles [17]. The next step in CTC research
is currently being undertakenby the Southwestern Oncology
Group (SWOG: S0500) via a phase three randomized trial
looking at changing therapy versus maintaining therapy in
metastatic breast cancer patients who have elevated CTC
levels after the ﬁrst followup visit upon treatment initiation.
Lastly, it has been recently shown in a mouse model
for metastatic breast cancer that CTCs can also colonize
their tumor of origin. This work completed by Kim et
al. has been referred to as “tumor self-seeding.” In their
experimental model, the primary tumor was able to be
seeded by separate tumor masses, metastatic lesions, and
from direct inoculation. They found that the primary tumor
secretes several cytokines that attract the CTCs, such as IL-
6 and IL-8. In turn, once the CTCs have inﬁltrated the
tumor, they secrete factors that inﬂuence the primary tumor
microenvironment, including tumor growth, angiogenesis,
and leukocyte recruitment. Thus, once further elucidated,
the factors involved in CTC-primary tumor interactions
allow for potential therapeutic targets [55].
6.EarlyBreast Cancer
There have been few studies regarding CTCs and early breast
cancer. The reported CTC positivity rate has ranged from
9.4 to 48.6% [20, 22, 23, 56–67]. Several of these studies
have tried to identify primary tumor characteristics that
would predict the presence of CTCs. A recent study by
Krishnamurthy et al. looked at DTCs and CTCs in stage 1
and 2 breast cancer patients and found that the presence of
bothDTCsandCTCswasindependentoflymphnodestatus,
tumor grade, tumor size, and receptor status [64]. This is
in contrast with early ﬁndings of the SUCCESS trial. This
trial is looking at CTCs at the time of primary diagnosis as
well asduringadjuvantchemotherapy.Theyreport apositive4 Pathology Research International
correlationbetweenlymphnodesstatusandCTCs[68].Lang
et al. looked at both CTCs and DTCs and found that only
HER2 status of the primary tumor was associated with the
presence of CTCs [62]. In contrast to previous studies, both
Krishnamurthy etal.andLangetal.didnotﬁndacorrelation
between the presence of CTCs with DTCs [62].
Severalstudiesinvolving early breast cancerpatientshave
shown that the presence of CTCs is associated with a worse
prognosis. Wulﬁng et al. used a buoyant density gradient and
immunomagnetic separation technique to look at HER2-
positive CTCs in stage 1 through stage 3 breast cancer
patients. They found that 17/35 (48.6%) patients had HER2-
positive CTCs, of which twelve of these patients had HER2-
negative primary tumors. The presence of HER2-positive
CTCs was associated with a signiﬁcantly decreased disease-
free survival andoverallsurvival [65].Thiswasvalidatedbya
recentlargestudyof216patientsusinganRT-PCRtechnique
to look at HER2-mRNA-positive CTCs [23].
Other studies have looked at RT-PCR techniques using
mammaglobin A and CK-19. Ignatiadis et al. used a triple
primer RT-PCR technique using CK19, mammaglobin A,
and HER2 in 175 women with early breast cancer. They
found that the presence of CK-19 mRNA-positive and mam-
maglobin A mRNA-positive CTCs prior to the initiation of
adjuvanttherapywas associated withadecreaseddisease-free
survival [59]. However, a previous study by Ignatiadis et al.
looking at 444 early stage breast cancer patients found that
the presence of CK-19 mRNA-positive CTCs was associated
with a reduced disease-free survival in only ER-negative,
triple-negative, and HER2-positive patients [60]. Xenidis et
al. looked at 167 node-negative breast cancer patients and
found that the presence of CK-19 mRNA-positive CTCs was
associated with both early clinical relapse and disease-related
death [58]. Ntoulia et al. and Ferro et al. found that
mammaglobin A mRNA positivity was associated with a
poorer prognosis [61, 67].
7.TreatmentMonitoring
One goal of CTC detection is to be correlate CTC levels to
disease progression and response to treatment. In early
breast cancer, some studies have found a correlation between
initial CTC reduction upon therapy initiation and the ﬁnal
response of the tumor [69, 70]. However, most studies in
early breast cancer do not support a correlation between
CTC response and tumor response. The GeparQuattro
study looked at CTC levels at the time of diagnosis
and after neoadjuvant therapy in 213 large operable and
locallyadvanced breastcancerpatients. Neoadjuvanttherapy
included trastuzumab if the primary tumor was HER2 posi-
tive. The incidence of CTCs went from 21.6% before treat-
ment to 10.6% after treatment. Fifteen percent of initially
CTC-positive patients became CTC negative after treatment,
and 8.3% of initially CTC-negative patients became CTC-
positive after treatment. However, no signiﬁcant correlation
was found between CTC detection and the primary tumor’s
response to neoadjuvant therapy [20]. Pierga et al. found
similar results in a study of 118 stage 2-3 breast cancer
patients using the CellSearch System. Though 23/118 (19%)
patients had a complete response to neoadjuvant therapy,
changes in CTC count did not correlate with tumor response
[66].
Though data is inconsistent regarding tumor response,
most studies have found that the presence of CTCs does
predict early relapse. The SUCCESS trial looked at 1,489
nonmetastatic breast cancer patients using the CellSearch
System and found that pretreatment CTC detection was
associatedwithreduceddisease-free survivalaswellasoverall
survival, while post treatment CTC detection was only
associated with reduced disease-free survival [68]. Similar
results were shown in the previously described study by
Pierga et al. [66]. The data from Pierga et al.’s study was
further analyzed after a longer followup period (18 months
versus 36.4 months) and concluded that preneoadjuvant
CTC detection is a better predictor of overall survival and
distant metastasis-free survival than post-treatment CTC
detection [56]. Xenidis et al. looked at 437 early stage breast
cancerpatients and found bothpre- and post-treatment CK-
19 mRNA-positive CTCs to be associated with decreased
disease-free and overall survival [58]. Apostolaki et al.
looked at HER2 mRNA-positive CTCs in 214 stage 1 and 2
breast cancer patients. Initially HER2 mRNA positivity was
21%. Adjuvant chemotherapy was able to eliminate CTCs
in 16/53 (30.2%) of patients. The presence of CTCs after
treatment was associated with reduced disease-free interval
[22]. Similar results were reported in a study looking at
adjuvant therapy which found that an increase in CTC level
of tenfold or higher, independent of an initial response,
predicted early relapse [71].
Several studies have looked speciﬁcally at CTCs dur-
ing treatment with hormonally therapy. Pachmann et al.
recently found that escalating numbers of CTCs during
Tamoxifen treatment was a strong predictor of relapse. This
increase was also predictive of subsequent relapse during
aromatase inhibitor treatment [72]. Furthermore, Xenidis et
al. reported a reduced disease-free interval as well as overall
survival with persistent CK-19 mRNA CTC positivity after
treatment with Tamoxifen [73].
8.ConclusionandFutureDirections
Evidence has shown that CTCs play a prognostic role in
both early and metastatic breast cancer patients. In early
breast cancer, the presence of CTCs allows clinicians to
identify those patients that are at risk for recurrence and
therefore may beneﬁt from additional therapy. In both
early and metastatic breast cancer patients, CTCs are an
easily assessable source for monitoring treatment eﬃcacy.
Though results from the SWOG trial are pending, CTC
monitoring may allow oncologists to change therapy earlier
in disease progression. Lastly, with molecular and genetic
characterization of CTCs, chemoresistance proﬁles should
also be able to advise the clinician of the most eﬃcacious
chemotherapy regimens.
In terms of tumor biology, it is clear that circulating
tumorcells are present in early breast cancer thussupportingPathology Research International 5
the theory of early metastasis. One question yet to be an-
swered is exactly how early in the neoplastic process does
tumor dissemination occur. Studies have yet to look at the
presence of CTCs in ductal carcinoma in situ (DCIS). Not
all CTCs may lead to metastatic deposits as the metastatic
niche may need to be created. Furthermore, even in early
breast cancer, CTCs show great diversity compared to the
primary tumor. Of particular interest is the diversity in
HER2 status. It may be possible to target CTC/DTC to
eradicate potential metastatic deposits. Targeting CTC using
vaccines against HER2 and other pathways involved with
breast cancer could theoretically decrease the probability of
CTC seeding, recurrence, and/or metastasis [74–77].
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